<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2086498-B1" country="EP" doc-number="2086498" kind="B1" date="20140108" family-id="39223072" file-reference-id="306753" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588304" ucid="EP-2086498-B1"><document-id><country>EP</country><doc-number>2086498</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-07853075-A" is-representative="NO"><document-id mxw-id="PAPP154850496" load-source="docdb" format="epo"><country>EP</country><doc-number>07853075</doc-number><kind>A</kind><date>20071102</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140549527" ucid="US-2007023183-W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2007023183</doc-number><kind>W</kind><date>20071102</date></document-id></priority-claim><priority-claim mxw-id="PPC140550343" ucid="US-59268406-A" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>59268406</doc-number><kind>A</kind><date>20061103</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130709</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989325227" load-source="ipcr">A61K   8/20        20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325228" load-source="ipcr">A61K   8/34        20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325229" load-source="ipcr">A61K   8/44        20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325230" load-source="ipcr">A61K   8/49        20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325231" load-source="ipcr">A61K   8/60        20060101AFI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325232" load-source="ipcr">A61K   8/84        20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325233" load-source="ipcr">A61K   9/00        20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325234" load-source="ipcr">A61K  31/047       20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325235" load-source="ipcr">A61K  31/155       20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325236" load-source="ipcr">A61Q  17/00        20060101ALI20130108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325237" load-source="ipcr">A61Q  19/10        20060101ALI20130108BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989620079" load-source="docdb" scheme="CPC">A61K   8/442       20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989620282" load-source="docdb" scheme="CPC">A61K   8/345       20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989631114" load-source="docdb" scheme="CPC">A61Q  19/10        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989633097" load-source="docdb" scheme="CPC">A61K  31/155       20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989638142" load-source="docdb" scheme="CPC">A61K  31/047       20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989640083" load-source="docdb" scheme="CPC">A61Q  17/005       20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989640196" load-source="docdb" scheme="CPC">A61K   8/84        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989641516" load-source="docdb" scheme="CPC">A61K2800/28        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989641705" load-source="docdb" scheme="CPC">A61K   9/0048      20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989646197" load-source="docdb" scheme="CPC">A61K   8/4993      20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989648305" load-source="docdb" scheme="CPC">A61K   8/604       20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989648572" load-source="docdb" scheme="CPC">A61K2800/52        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989649594" load-source="docdb" scheme="CPC">A61K   8/20        20130101 LI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369545" lang="DE" load-source="patent-office">AUGENLID-REINIGUNGSZUSAMMENSETZUNG</invention-title><invention-title mxw-id="PT132369546" lang="EN" load-source="patent-office">EYELID SCRUB COMPOSITION</invention-title><invention-title mxw-id="PT132369547" lang="FR" load-source="patent-office">COMPOSITION NETTOYANTE POUR PAUPIÈRE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919507993" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>OCUSOFT INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919530235" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>OCUSOFT, INC.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919533865" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>WITHAM PATRICK</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919546134" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>WITHAM, PATRICK</last-name></addressbook></inventor><inventor mxw-id="PPAR919022478" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>WITHAM, PATRICK</last-name><address><street>5563 Jeffrey Way</street><city>Eugene, Oregon 97402</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919532657" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ADKINS NAT G JR</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919524978" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ADKINS, NAT G., JR.</last-name></addressbook></inventor><inventor mxw-id="PPAR919022479" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>ADKINS, NAT G., JR.</last-name><address><street>P.O. Box 429</street><city>Richmond, TX 77405</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919503949" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>BANOV DANIEL</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919534528" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>BANOV, DANIEL</last-name></addressbook></inventor><inventor mxw-id="PPAR919022476" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>BANOV, DANIEL</last-name><address><street>1302 Gray Hills Ct.</street><city>Sugar Land, TX 77479</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919522574" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>BASSANI AUGUST</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919511958" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>BASSANI, AUGUST</last-name></addressbook></inventor><inventor mxw-id="PPAR919022477" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>BASSANI, AUGUST</last-name><address><street>9901 S.Wilcrest Drive</street><city>Houston, TX 77099-5132</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919022481" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Ocusoft, Inc.</last-name><iid>101037633</iid><address><street>5311 Avenue N.</street><city>Rosenburg, TX 77471</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919022480" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Müller Schupfner &amp; Partner</last-name><iid>101297565</iid><address><street>Schellerdamm 19</street><city>21079 Hamburg</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2007023183-W"><document-id><country>US</country><doc-number>2007023183</doc-number><kind>W</kind><date>20071102</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2008057442-A2"><document-id><country>WO</country><doc-number>2008057442</doc-number><kind>A2</kind><date>20080515</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549869056" load-source="docdb">AT</country><country mxw-id="DS549872115" load-source="docdb">BE</country><country mxw-id="DS549783683" load-source="docdb">BG</country><country mxw-id="DS549923511" load-source="docdb">CH</country><country mxw-id="DS549872116" load-source="docdb">CY</country><country mxw-id="DS549869057" load-source="docdb">CZ</country><country mxw-id="DS549784505" load-source="docdb">DE</country><country mxw-id="DS549872117" load-source="docdb">DK</country><country mxw-id="DS549872122" load-source="docdb">EE</country><country mxw-id="DS549801574" load-source="docdb">ES</country><country mxw-id="DS549783684" load-source="docdb">FI</country><country mxw-id="DS549923512" load-source="docdb">FR</country><country mxw-id="DS549784506" load-source="docdb">GB</country><country mxw-id="DS549872123" load-source="docdb">GR</country><country mxw-id="DS549869062" load-source="docdb">HU</country><country mxw-id="DS549923513" load-source="docdb">IE</country><country mxw-id="DS549872124" load-source="docdb">IS</country><country mxw-id="DS549783689" load-source="docdb">IT</country><country mxw-id="DS549872125" load-source="docdb">LI</country><country mxw-id="DS549783690" load-source="docdb">LT</country><country mxw-id="DS549878010" load-source="docdb">LU</country><country mxw-id="DS549783691" load-source="docdb">LV</country><country mxw-id="DS549783692" load-source="docdb">MC</country><country mxw-id="DS549878011" load-source="docdb">MT</country><country mxw-id="DS549872130" load-source="docdb">NL</country><country mxw-id="DS549872131" load-source="docdb">PL</country><country mxw-id="DS549783697" load-source="docdb">PT</country><country mxw-id="DS549869063" load-source="docdb">RO</country><country mxw-id="DS549872132" load-source="docdb">SE</country><country mxw-id="DS549923514" load-source="docdb">SI</country><country mxw-id="DS549784507" load-source="docdb">SK</country><country mxw-id="DS549878012" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960729" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b><u>FIELD OF THE INVENTION</u></b></heading><p id="p0001" num="0001">The present invention relates to an anti-microbial composition. Further, the invention relates to compositions useful as eyelid scrubs.</p><heading id="h0002"><b><u>BACKGROUND OF THE INVENTION</u></b></heading><p id="p0002" num="0002">The eyelids are important to over-all ocular health because they protect the eyes from dangers such as approaching objects or from airborne contaminants, such as pollen, dust particles or other foreign bodies. The eyelids contain several glands including the lacrimal glands and meibomian glands that produce layers of tear film that are critical for healthy eyes. When an individual blinks, a new tear film is created and tears are distributed across the cornea to lubricate the surface of the eye. This blinking action also "flushes" foreign materials from the eye.</p><p id="p0003" num="0003">The eyelids, however, are subject to certain problems, which while common, are none-the-less bothersome, especially for contact lens wearers, and may lead to other, more serious complications. One complication is staphylococcal blepharitis (blepharitis). Blepharitis is a common chronic inflammation of the eyelids characterized by a scaly crust on the lid margins. The condition may be caused by a bacterial infection, or it may be allergic in<!-- EPO <DP n="2"> --> origin or associated with seborrhea of the face and scalp. Treatment usually involves cleansing the eyelids on a regular basis to remove excess oil, debris, and desquamated skin that may be problematic.</p><p id="p0004" num="0004">Often associated with or secondary to blepharitis is a bacterial infection of the surface of the skin at the edge of the lid, known as an internal hordeolum. Other such infections include external hordeolum, commonly referred to styes, which are infections of the tiny oil secreting meibomian glands along the edge of the eyelid, surrounding the eyelashes. A stye begins as a red, tender bump and usually fully develops within three days. Such conditions are accompanied by pain, redness and tenderness of the lid margins. Although styes are often recurring, regular cleansing of the eyelid margins can minimize such conditions. A second problem is a chalazion, which is an inflammation of the meibomian glands inside the eyelid. Chalazia typically grow slowly over 2-3 weeks and although they do not typically cause pain, they often require surgical intervention if left untreated.</p><p id="p0005" num="0005">With any of the above-described problems, as well as other medical complications, such as rosacea and seborrhea, proper eyelid hygiene with the use of an eyelid cleanser may minimize the severity of the outbreak, or prevent the problem altogether if caught early. Eyelid cleansers are also used for cleaning eyelashes, eyelids or the periocular area and may be used as a preoperative<!-- EPO <DP n="3"> --> scrub to help reduce the presence of harmful bacteria which may cause infection, inflammation, or even endophthalmitis in patients.</p><p id="p0006" num="0006">Endophthalmitis is an intraocular infection that commonly occurs after cataract surgery. The causative agent in post-operative endopthalmitis is typically a bacteria, often the causative bacteria is Staphylococcus Epidermidis. To prevent post-operative endopthalmitis as well as blepharitis, an eyelid scrub is often used to cleanse the eyelid.</p><p id="p0007" num="0007">Often simple skin cleansers are unsuited for use on the eyelid. Eyelid cleansers must be non-irritating to both the sensitive skin around the eye and the eye tissue itself, while having an antimicrobial effect. One factor causing eye irritation is an abnormal pH level of the eyelid cleaner composition. Non-irritating formulations should have a pH level which is close to neutral, 7.0. Many skin cleaners have a pH outside this range. To control the pH level of skin cleanser a traditional pH adjuster is often employed. Traditional pH adjusters include basic pH adjusters, such as ammonia, mono-, di- and tri-alkyl amines, mono-, di- and tri-alkanolamines, alkali metal and alkaline earth metal hydroxides (e.g., ammonia, sodium hydroxide, potassium hydroxide, lithium hydroxide, monoethanolamine, triethylamine, isopropylamine, diethanolamine and triethanolamine), and acidic pH adjusters, such as mineral acids and polycarboxylic acids (e.g., hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, citric acid, glycolic acid, and lactic acid). Unfortunately, pH adjusters can<!-- EPO <DP n="4"> --> also cause eye irritation themselves. Therefore, there is a need for an eyelid scrub composition which is effective at killing bacteria, but does not include traditional pH adjusters, so that it is gentle enough to be used around the eye.</p><heading id="h0003"><u>SUMMARY</u></heading><p id="p0008" num="0008">The composition of the present invention is effective as an anti-microbial, while being minimally irritating to the eye. The composition comprises polyhexamethylene biguanide (PHMB), 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5. The use of a surfactant solution to control pH rather than traditional pH adjusters, makes the composition less irritating to the eye. Also, the foaming capability of the surfactant solution included in the composition increases its cleansing ability.</p><p id="p0009" num="0009">In one embodiment, the pH stabilizing surfactant solution comprises cocoamphodiacetate disodium, polyoxyethylene 80 sorbitan monolaurate, decyl polyglucoside, and a modified Ringer's solution.</p><p id="p0010" num="0010">In another embodiment, the composition also includes moisturizers, such as methyl gluceth-20, sorbitol, glycerine, glycols, propylene glycol, carboxylates, amino acids, glucoside derivatives, urea, lactates, and derivatives of pantothenic acid.<!-- EPO <DP n="5"> --></p><p id="p0011" num="0011">The composition is produced by preparing a modified Ringer's solution by mixing electrolytes in water and mixing 1,2-hexanediol,1,2-octanediol, and an effective amount of one or more pH stabilizing surfactants with the modified Ringer's solution. The mixture is then heated and allowed to cool before polyhexamethylene biguanide is added.</p><p id="p0012" num="0012">The composition may be applied to the eyelid by applying an effective amount of the composition to the eyelid. Optionally, the composition may be rubbed onto the eyelid to induce foaming.</p><p id="p0013" num="0013">The composition can be combined with a fabric pad for use as an eyelid scrub. The fabric pad is pre-moistened with the composition and packaged for use.</p><heading id="h0004"><b><u>BRIEF DESCRIPTION OF THE DRAWINGS</u></b></heading><p id="p0014" num="0014"><ul><li><figref idrefs="f0001">Fig. 1</figref> is a top view of the fabric pad of the invention.</li><li><figref idrefs="f0001">Fig. 2</figref> is a top view of the container for the fabric pad.</li></ul></p><heading id="h0005"><b><u>DETAILED DESCRIPTION</u></b></heading><p id="p0015" num="0015">The composition of the invention is effective as an eyelid cleanser, or scrub, as it has an antimicrobial effect, but is still practically non-irritating to the eye. The composition has these beneficial characteristics because of the combination of polyhexamethylene biguanide (PHMB) and Symdiol. Symdiol is a<!-- EPO <DP n="6"> --> combination of 1,2-hexanediol and 1,2-octanediol. The PHMB-Symdiol combination has a synergistic anti-microbial effect. In addition, the composition of this invention avoids traditional pH adjusters by using a pH stabilizing surfactant solution. Elimination of traditional pH adjusters reduces the amount of irritation caused by the composition in comparison to prior eyelid cleansers.</p><p id="p0016" num="0016">The eyelid scrub composition of this invention comprises polyhexamethylene biguanide (PHMB), 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5.</p><p id="p0017" num="0017">For the purposes of this invention, polyhexamethylene biguanide (PHMB) is pseudonymous for polyhexamethylene biguanide, polyhexamethylene biguanide hydrochloride, and polyaminopropyl biguanide. PHMB is available in a 20% aqueous solution sold under the tradename Cosmocil ® by Arch Personal Care Products L.P. The combination of 1,2-hexanediol and 1,2-octanediol is sold under the tradename Symdiol 68 by Symrise. 1,2-octanediol is also known as caprylyl glycol. Combining PHMB with 1,2-hexanediol and 1,2-octanediol has a synergistic antimicrobial effect.</p><p id="p0018" num="0018">To avoid the irritating effects of traditional pH adjusters, the pH stabilizing surfactant solution is prepared to provide a pH stabilized composition. Surfactants also increase cleansing ability of the composition and have a<!-- EPO <DP n="7"> --> foaming capability. PHMB is most effective as an antimicrobial agent in pH ranges between 5.5 and 7.5. Therefore, it is desirable to control the pH level of the composition within this range by use of a blend of surfactants. It is also desirable that the eyelid scrub of the present invention has a foaming ability to facilitate physical cleansing of the eyelid. Consequently, surfactants must be chosen which will both control the pH of the composition within PHMB's effective range and provide the foaming ability necessary to physically clean the eyelid.</p><p id="p0019" num="0019">Advantageously, controlling the pH of the composition with a surfactant solution rather than traditional pH adjusters has safety benefits as many traditional pH adjusters are irritating to the eye. In general, surfactants are less irritating to the eye than traditional pH adjusters. Examples of traditional pH adjusters, include basic pH adjusters, such as ammonia, mono-, di- and tri-alkyl amines, mono-, di- and tri-alkanolamines, alkali metal and alkaline earth metal hydroxides (e.g., ammonia, sodium hydroxide, potassium hydroxide, lithium hydroxide, monoethanolamine, triethylamine, isopropylamine, diethanolamine and triethanolamine), and acidic pH adjusters, such as mineral acids and polycarboxylic acids (e.g., hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, citric acid, glycolic acid, and lactic acid).</p><p id="p0020" num="0020">In addition to reduced irritation, many surfactants have the added capability of producing a foam which assists in the cleansing ability of the composition. To form the pH stabilizing surfactant solution, one or more foam<!-- EPO <DP n="8"> --> producing surfactants are first chosen to provide the foaming ability of the composition. Suitable surfactants include anionic, nonionic, and amphoteric surfactants. In one embodiment, both polyoxyethylene 80 sorbitan monolaurate and decyl polyglucoside are used as the foam producing surfactants.</p><p id="p0021" num="0021">To control the pH of the composition, one or more additional surfactants may be required in the pH stabilizing surfactant solution to compensate for the pH level of the foam producing surfactants. To determine whether a pH compensating surfactant is required, the pH of the foam producing surfactants is measured and a pH compensating surfactant is chosen to control the pH of the solution within the desired range. For example, if the pH level of the foam producing surfactants is in the acidic range, i.e. less that 7.0, a pH compensating surfactant in the basic range is chosen. Suitable pH compensating surfactants include both foaming and non-foaming surfactants, which further include anionic, nonionic, and amphoteric surfactants. In one embodiment, the pH compensating surfactant is cocoamphodicetate disodium.</p><p id="p0022" num="0022">The combination of surfactants is added to a modified Ringer's solution. For the purposes of this invention, a modified Ringer's solution is an isotonic aqueous solution of electrolytes which is physiologically compatible with human tissue. In one embodiment, the modified Ringer's solution comprises sodium chloride, potassium chloride, calcium chloride, and water. Modified Ringer's<!-- EPO <DP n="9"> --> solution is included in the surfactant solution to ensure that the composition will not remove water from human tissue by osmosis.</p><p id="p0023" num="0023">The combination of surfactants and modified Ringer's solution are mixed with the combination of PHMB, 1,2-hexanediol, and 1,2-octanediol to form the eyelid scrub composition. To determine the correct amount of each surfactant to include in the eyelid scrub composition, the pH of the entire composition, the foaming capacity of composition, and the cleansing ability of the composition are tested. The pH level of the composition is measured with a pH meter and the amount of the individual surfactants adjusted to control the composition's pH within the desired pH range.</p><p id="p0024" num="0024">The composition's foaming capability is measured according to the Ross Miles method. This measurement involves producing foam from the composition and measuring the height and stability of the foam over time. The foam is created by pouring the composition from a set height into itself for five minutes. Alternatively, where the composition has a low foam capability, the composition is agitated with a turbine agitator for a set time to produce the foam. The thickness of the foam is measured at timed intervals. To achieve the desired foaming capability, the amounts of foam producing surfactants in the composition are varied.<!-- EPO <DP n="10"> --></p><p id="p0025" num="0025">A-06020 WO/EP Replacement Page 10</p><p id="p0026" num="0026">Finally, the cleansing capabilities of the composition are tested by anecdotal human testing. Humans apply the composition to the eyelid and cleanse the eyelid. The humans report the levels of irritation, skin tightness and overall feeling of cleanness caused by the composition. The amounts and types 5 of surfactants employed are adjusted in response to the reports.</p><p id="p0027" num="0027">Through the adjustment of the amounts and types of surfactants used in the pH stabilizing surfactant solution in response to test results of the pH level, foaming capacity, and cleansing capabilities, an effective amount of pH stabilizing surfactant composition to be used is determined. The combination of the pH stabilizing surfactant solution with PHMB, 1,2-hexanediol and 1,2-octanediol forms the composition of this invention.</p><p id="p0028" num="0028">In a first embodiment, the composition of this invention comprises PHMB, 5 1,2-hexanediol, and 1,2-octanediol in combination with a pH stabilizing surfactant solution. Suitable surfactants to be used in the pH stabilizing surfactant solution include amphoteric surfactants, anionic surfactants, and nonionic surfactants. Suitable amphoteric surfactants include, but are not limited to alkyldimethyl betaines, alkylamido betaines, sulfobetaines, and imidazoline amphoterics. Suitable anionic surfactants include, but are not limited to fatty alcohol sulfates, alpha olefin sulfonates, sulfosuccinates, sarcosinates, phosphate esters, and carboxylates. Suitable nonionic surfactants include, but are not limited to<!-- EPO <DP n="11"> --> alkanolamids, ethoxylate amids, esters, alxylated alcohols, alkylpolyglucosides, amine oxides, sorbitan esters, and ethoxylates.</p><p id="p0029" num="0029">In one embodiment, the pH stabilizing surfactant solution comprises cocoamphodiacetate disodium, polyoxyethylene 80 sorbitan monolaurate, decyl polyglucoside, and a modified Ringer's solution. Cocoamphodiacetate disodium is an amphoteric surfactant. Polyoxyethylene 80 sorbitan monolaurate and decyl polyglucoside are both nonionic surfactants. In another embodiment, the composition, when mixed, comprises about 0.1 to 25 wt.% cocoamphodiacetate disodium, 0.1 to 10 wt.% polyoxyethylene 80 sorbitan monolaurate, 0.2 to 10 wt.% decyl polyglucoside, and 60 to 98 wt.% modified Ringer's solution.</p><p id="p0030" num="0030">In another embodiment of the invention, the modified Ringer's solution comprises, sodium chloride, potassium chloride, calcium chloride, and water. Preferably, the water used is purified water. The modified Ringer's solution may also comprise 0.05 to 1.2 wt. % sodium chloride, 0.005 to 0.5 wt. % potassium chloride, 0.005 to .5 wt. % calcium chloride, and water. In still another embodiment, the modified Ringer's solution comprises about 0.7 wt. % sodium chloride, about 0.03 wt. % potassium chloride, about 0.033 wt. % calcium chloride, and purified water.</p><p id="p0031" num="0031">In still another embodiment, the composition of this invention can further comprise one or more moisturizers. Moisturizers are chemicals that prevent<!-- EPO <DP n="12"> --> transepidermal water loss. Moisturizers may prevent water loss by forming a film over the skin to prevent water from evaporating from the skin. Alternatively, moisturizers comprise hydroscopic molecules that draw water from the air into the skin. Suitable moisturizers include, but are not limited to, methyl gluceth-20, sorbitol, glycerine, propylene glycol, carboxylates, amino acids, glucoside derivatives, urea, lactates, and derivatives of pantothenic acid. Examples of derivatives of pantothenic acid include panthenol, D-panthenol, and D, L-panthenol.</p><p id="p0032" num="0032">In a further embodiment, the composition also comprises a foam stabilizer. A foam stabilizer is a chemical which increases the lifetime of the foam. The foam stabilizer can be a polyethylene glycol diester of methyl glucose and a fatty acid. Suitable fatty acids include oleic acid, steric acid, lauric acid, caprylic acid, and capric acid. Suitably, the foam stabilizer is PEG-120 methyl glucose dioleate.</p><p id="p0033" num="0033">One specific embodiment of the composition comprises polyhexamethylene biguanide, 1,2-hexanediol,1,2-octanediol, D-panthenol, cocoamphodiacetate disodium, polyoxyethylene-80 sorbitan monolaurate, decyl polyglucoside, methyl gluceth-20, and PEG-120 methyl glucose dioleate. Decyl polyglucoside is sold under the tradename Oramix NS10 by Seppic, Inc. Polyoxyethylene-80 sorbitan monolaurate is sold under the tradename T-MAZ ® 28 by BASF Corporation. Cocoamphodiacetate disodium is sold under the<!-- EPO <DP n="13"> --> tradename Mackam 2C by The Mcintyre Group. Methyl gluceth-20 is sold under the tradename Glucam ® E-20 by Dow. PEG-120 methyl glucose dioleate is sold under the tradename Glucamate DOE-120 by Dow. D-panthenol is also known as Dexpanthenol and is available from Dow.</p><p id="p0034" num="0034">Another specific embodiment of the composition comprises about 0.02 wt.% to about 0.3 wt.% PHMB, about 0.05 wt.% to about 2.0 wt.% 1,2-hexanediol, about 0.05 wt.% to about 2.0 wt.% 1,2-octanediol, about 0.1 wt.% to about 25 wt.% cocoamphodiacetate disodium, about 0.1 wt.% to about 10 wt.% polyoxyethylene 80 sorbitan monolaurate, about 0.2 wt.% to about 10 wt.% decyl polyglucoside, and about 60 wt.% to about 98 wt.% Modified Ringer's Solution.</p><p id="p0035" num="0035">Yet another specific embodiment of the composition comprises about 0.04 wt.% polyhexamethylene biguanide, about 0.2 wt.% 1,2-hexanediol, about 0.2 wt.% 1,2-octanediol, about 0.2 wt.% D-panthenol, about 0.215 wt.% cocoamphodiacetate disodium, about 4.032 wt.% polyoxyethylene 80 sorbitan monolaurate, about 0.275 wt.% decyl polyglucoside, about 4.3 wt.% methyl gluceth-20, about 0.6 wt.% PEG-120 methyl glucose dioleate, about 87.985 wt.% Modified Ringer's Solution, and water.</p><heading id="h0006">ZINC FREE</heading><p id="p0036" num="0036">Zinc salts are astringents which cause skin to tighten. The skin around the ocular area is more sensitive that other areas of skin. The inclusion of a zinc salt<!-- EPO <DP n="14"> --> is a composition may be undesirable as its astringent property would make the composition more irritating to the eyelid area. Therefore in one embodiment, the composition comprises PHMB, 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution, but is also essentially free of zinc salts. Examples of zinc salts include zinc acetate, zinc lactate, zinc gluconate, zinc citrate, zinc butyrate, and zinc sterate.</p><heading id="h0007">METHODS</heading><p id="p0037" num="0037">To produce the composition of this invention, the modified Ringer's solution is made by mixing electrolytes in water. Symdiol, a combination of 1,2--hexanediol and 1,2-octanediol, is mixed with the modified Ringer's solution along with the surfactants that comprise the pH stabilizing surfactant solution. The mixture is then heated to dissolve the solids into solution. The mixture is then allowed to cool before the polyhexamethylene biguanide is added. In one aspect of the method, the mixture is heated to about 60° C. In another aspect, the mixture is allowed to cool until its temperature reaches about 40° C.</p><p id="p0038" num="0038">In another embodiment of the method of producing the composition, the modified Ringer's solution is made by mixing sodium chloride, potassium chloride, and calcium chloride with water. In still another embodiment, one or more moisturizers are also added to the modified Ringer's solution. A foam stabilizer may also be included.<!-- EPO <DP n="15"> --></p><p id="p0039" num="0039">The composition of the present invention may be used to cleanse an eyelid. The eyelid scrub is useful in preoperative sterilization of the eyelid and in everyday application for the prevention of various diseases of the eyelid, such as blepharitis. To cleanse the eyelid, an effective amount of the eyelid scrub is applied to the eyelid. The eyelid scrub comprises polyhexamethylene biguanide, 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5. The eyelid scrub may be rubbed on the eyelid to induce foaming, which facilitates cleansing of the eyelid. Advantageously, the eyelid scrub of this invention can be mild enough that it can be allowed to remain on the eyelid after cleansing, without rinsing. The ability of the eyelid scrub to be left on the eyelid rather than rinsed off increases the composition's anti-microbial effect. In general, the longer an anti-microbial composition is allowed to contact the pathogens, the more pathogens it will kill.</p><p id="p0040" num="0040">In another aspect of the method of using the composition of this invention, the eyelid scrub is applied to the eyelid from a fabric pad. The eyelid scrub may be rubbed on the eyelid with a fabric pad to induce foaming, which assists in the cleansing ability of the eyelid scrub.</p><heading id="h0008">PRE-MOISTENED PADS</heading><p id="p0041" num="0041">Referring now to <figref idrefs="f0001">Fig. 1</figref>, the composition of the present invention may be combined with a fabric pad 1 to form an apparatus for cleansing eyelids. In a first<!-- EPO <DP n="16"> --> embodiment, the apparatus comprises a fabric pad 1 pre-moistened with an eyelid scrub composition. The eyelid scrub composition comprising polyhexamethylene biguanide, 1,2-hexanediol,1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5. In one aspect, the fabric pad 1 comprises a rayon and polypropylene fabric blend. In another aspect, the fabric pad comprises a textured surface 2.</p><p id="p0042" num="0042">Referring now to <figref idrefs="f0001">Fig. 2</figref>, in another embodiment, the apparatus further comprises a sealable container 3 enclosing the pre-moistened fabric pad. In one aspect, the sealable container 3 may comprise a box, or a package. The package may be made of any suitable material including plastic or a metal foil material. The pre-moistened fabric pads may be individually packaged for use. In still another embodiment, the apparatus comprises 1.3 to 1.5 grams of eyelid scrub. Preferably, the 1.4 grams of eyelid scrub are used.</p><heading id="h0009">TEST RESULTS</heading><p id="p0043" num="0043">The composition of the present invention has an anti-microbial effect with a lower level on irritation than other antimicrobial compositions. To confirm the characteristic of the composition of this invention both the irritation and antimicrobial effects of the composition were tested. These results were compared to another commonly available composition, Sterelid®.<!-- EPO <DP n="17"> --></p><p id="p0044" num="0044">One embodiment of the composition of this invention was tested for both irritation and anti-microbial effect, hereafter referred to as Composition 1. Composition 1 contained polyhexamethylene biguanide, 1,2-hexanediol, 1,2-octanediol, D-panthenol, cocoamphodiacetate disodium, polyoxyethylene 80 sorbitan monolaurate, decyl polyglucoside, methyl gluceth-20, PEG-120 methyl glucose dioleate, Modified Ringer's Solution, and water.</p><p id="p0045" num="0045">For comparison a commonly available eyelid scrub was also tested. Sterilid®, available from Advanced Vision, contains water, PEG-80, sorbitan laurate, sodium trideceth sulfate, cocamidopropyl betaine, sodium lauroamphacetate, PEG-150 distearate, sodium laureth -13 carboxylate, linalool oil, hepes acetate, sodium perborate monohydrate, panthenol, allantoin, sodium chloride, tea tree oil, Tris-EDTA, boric acid, cocamidopropyl PG-dimonium chloride, etidronic acid, phosphonic acid, with citric acid and sodium hydroxide for pH adjustment.</p><p id="p0046" num="0046">To determine the irritation level of the composition, an eye irritation study was performed and the results scored on the Draize Scale for Scoring Ocular Lesions. The irritation testing was performed by placing 0.1 ml of the composition in the conjunctival sac of a rabbit's eye and recording the size and intensity of ocular irritation at 1, 24, 48, and 72 hours. The information is translated into a score on the Draize Scale which represents the irritation caused by the composition.<!-- EPO <DP n="18"> --></p><p id="p0047" num="0047">The results of the irritation testing for both Composition 1 and Sterilid are presented in Table 1. Composition 1 scored and 1.67 out of a possible 110.0 on the Draize Scale. A 1.67 is classified as "Practically Non-irritating" on the Draize Scale. Sterilid scored a 4.0 on the Draize Scale, which is classified as "Minimally Irritating."
<tables id="tabl0001" num="0001"><table frame="none"><title><u>Table 1</u></title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="34mm"/><thead><row><entry namest="col1" nameend="col2" align="center" valign="top">Eye Irritation Testing/Draize Score</entry></row><row><entry valign="top">Composition</entry><entry align="center" valign="top">Mean Irritation Score</entry></row></thead><tbody><row><entry>Composition 1</entry><entry align="center">1.67/110.0</entry></row><row><entry>Sterilid</entry><entry align="center">4.0/110.0</entry></row></tbody></tgroup></table></tables></p><p id="p0048" num="0048">Both Composition 1 and Sterilid were also subjected to time-kill studies to determine their effectiveness against the pathogen Staphylococcus Epidermidis (S. Epidermidis), which is a leading cause of post-operative endophthalmitis, a type of post-operative infection. The time-kill testing involved subjecting a suspension of the pathogen to the composition for 60 seconds and then neutralizing the composition. The pathogen was then plated and incubated for the appropriate amount of time. After incubation, the number of colonies of the pathogen were counted and the logarithmic reduction (Log Reduction) of the colony count from the control's colony count was calculated. The results of the time-kill study are presented in Table 2.<!-- EPO <DP n="19"> -->
<tables id="tabl0002" num="0002"><table frame="none"><title><u>Table 2</u></title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><thead><row><entry namest="col1" nameend="col2" align="center" valign="top">Time-Kill Testing of S. Epidermidis</entry></row><row><entry valign="top">Composition</entry><entry align="center" valign="top">Log Reduction</entry></row></thead><tbody><row><entry>Composition 1</entry><entry align="char" char="." charoff="7">5.5</entry></row><row><entry>Sterilid</entry><entry align="char" char="." charoff="7">3.5</entry></row></tbody></tgroup></table></tables>
Composition 1 was found to have a Log reduction of 5.5 of S. Epidermidis, while Sterilid was found to have Log reduction of 3.5 of S. Epidermidis. Composition 1's ability to kill the S. Epidermidis pathogen was therefore greater that Sterilid's.<br/>
The results of the irritation and time-kill testing indicate that Composition 1 was both more effective and less irritating than Sterilid, which uses citric acid and sodium hydroxide for pH adjustment rather than the pH modifying surfactant solution of the present invention.</p></description><claims mxw-id="PCLM56984924" lang="DE" load-source="patent-office"><!-- EPO <DP n="24"> --><claim id="c-de-01-0001" num="0001"><claim-text>Zusammensetzung, die Folgendes umfasst:
<claim-text>Polyhexamethylenbiguanid;</claim-text>
<claim-text>1,2-Hexandiol;</claim-text>
<claim-text>1,2-Octandiol; und</claim-text>
<claim-text>eine pH-stabilisierende Tensidlösung, die in einer Menge vorliegt, die ausreicht, um den pH-Wert der Zusammensetzung zwischen 5,5 und 7,5 zu halten,<br/>
wobei die pH-stabilisierende Tensidlösung aus einem oder mehreren Tensiden, ausgewählt aus einer Gruppe bestehend aus amphoteren Tensiden, anionischen Tensiden und nichtionischen Tensiden, besteht,<br/>
wobei die amphoteren Tenside aus einer Gruppe bestehend aus Alkyldimethylbetainen, Alkylamidobetainen, Sulfobetainen und Imidazolinamphoteren ausgewählt sind, wobei die anionischen Tenside aus einer Gruppe bestehend aus Fettalkoholsulfaten, alpha-Olfeinsulfonaten, Sulfosuccinaten, Sarcosinaten, Phosphatestern und Carboxylaten ausgewählt sind und wobei die nichtionischen Tenside aus einer Gruppe bestehend aus Alkanolamiden, Ethoxylatamiden, Estern, alkoxylierten Alkoholen, Alkylpolyglucosiden, Aminoxiden, Sorbitanestern und Ethoxylaten ausgewählt sind.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Zusammensetzung nach Anspruch 1, wobei die pHstabilisierende Tensidlösung Folgendes umfasst:
<claim-text>Dinatrium Cocoamphodiaretat;<!-- EPO <DP n="25"> --></claim-text>
<claim-text>Polyoxyethylen(80)-Sorbitanmonolaurat;</claim-text>
<claim-text>Decylpolyglucosid; und</claim-text>
<claim-text>eine modifizierte Ringer'sche Lösung.</claim-text></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Zusammensetzung nach Anspruch 2, wobei die Zusammensetzung Folgendes umfasst:
<claim-text>0,1 Gew.-% bis 25 Gew.-% Dinatrium Cocoamphodiaretat;</claim-text>
<claim-text>0,1 Gew.-% bis 10 Gew.-% Polyoxyethylen(80)-Sorbitanmonolaurat;</claim-text>
<claim-text>0,2 Gew.-% bis 10 Gew.-% Decylpolyglucosid; und 60 Gew.-% bis 98 Gew.-% modifizierte Ringer'sche Lösung.</claim-text></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Zusammensetzung nach Anspruch 2, wobei die modifizierte Ringer'sche Lösung Folgendes umfasst:
<claim-text>Natriumchlorid;</claim-text>
<claim-text>Kaliumchlorid;</claim-text>
<claim-text>Calciumchlorid; und</claim-text>
<claim-text>Wasser;</claim-text>
und vorzugweise
<claim-text>0,05 bis 1,2 Gew.-% Natriumchlorid;</claim-text>
<claim-text>0,005 bis 0,5 Gew.-% Kaliumchlorid;</claim-text>
<claim-text>0,005 bis 0,5 Gew.-% Calciumchlorid; und</claim-text>
<claim-text>Wasser,</claim-text>
und am stärksten bevorzugt
<claim-text>0,7 Gew.-% Natriumchlorid;</claim-text>
<claim-text>0,03 Gew.-% Kaliumchlorid;</claim-text>
<claim-text>0,033 Gew.-% Calciumchlorid; und</claim-text>
<claim-text>gereinigtes Wasser.</claim-text></claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Zusammensetzung nach Anspruch 1, die weiterhin Folgendes umfasst:
<claim-text>D-Panthenol;</claim-text>
<claim-text>Methyl Gluceth-20; und</claim-text>
<claim-text>PEG-120 Methyl Glucose Dioleat.</claim-text></claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Zusammensetzung nach Anspruch 1, die weiterhin einen oder mehrere feuchtigkeitsspendende Mittel<!-- EPO <DP n="26"> --> umfasst, vorzugweise ausgewählt aus einer Gruppe bestehend aus Methyl Gluceth-20, Sorbit, Glyzerin, Glykolen, Propylenglykol, Carboxylaten, Aminosäuren, Glucosidderivaten, Harnstoff, Laktaten sowie Derivaten der Pantothensäure, und wobei die Derivate der Pantothensäure am stärksten bevorzugt aus einer Gruppe bestehend aus Panthenol, D-Panthenol, D,L-Panthenol und Kombinationen davon ausgewählt sind.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Zusammensetzung nach Anspruch 1, die weiterhin einen Schaumstabilisator umfasst, wobei der Schaumstabilisator vorzugweise ein Polyethylenglykoldiester von Methylglukose und einer Fettsäure ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Zusammensetzung nach Anspruch 7, wobei die Fettsäure aus einer Gruppe bestehend aus Ölsäure, Stearinsäure, Laurinsäure, Caprylsäure und Caprinsäure ausgewählt ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Zusammensetzung nach Anspruch 1, wobei die Zusammensetzung im Wesentlichen frei von Zinksalzen ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Zusammensetzung nach Anspruch 2, die Folgendes umfasst:
<claim-text>Polyhexamethylenbiguanid;</claim-text>
<claim-text>1,2-Hexandiol;</claim-text>
<claim-text>1,2-Octandiol;</claim-text>
<claim-text>Dinatrium Cocoamphodiaretat;</claim-text>
<claim-text>Polyoxyethylen(80)-Sorbitanmonolaurat;</claim-text>
<claim-text>Decylpolyglucosid; und</claim-text>
<claim-text>eine modifizierte Ringer'sche Lösung,<br/>
wobei die Zusammensetzung weiterhin einen oder mehrere feuchtigkeitsspendende Mittel umfasst, wobei das feuchtigkeitsspendende Mittel vorzugweise aus einer Gruppe bestehend aus Methyl Gluceth-20, Sorbit, Glyzerin, Glykolen, Propylenglykol, Carboxylaten, Aminosäuren, Glucosidderivaten, Harnstoff, Laktaten und Derivaten der Pantothensäure ausgewählt ist.</claim-text><!-- EPO <DP n="27"> --></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Zusammensetzung nach Anspruch 10, die weiterhin Folgendes umfasst:
<claim-text>D-Panthenol;</claim-text>
<claim-text>Methyl Gluceth-20; und</claim-text>
<claim-text>PEG-120 Methyl Glucose Dioleat.</claim-text></claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Zusammensetzung nach Anspruch 10, die Folgendes umfasst:
<claim-text>0,04 Gew.-% Polyhexamethylenbiguanid;</claim-text>
<claim-text>0,2 Gew.-% 1,2-Hexandiol;</claim-text>
<claim-text>0,2 Gew.-% 1,2-Octandiol;</claim-text>
<claim-text>0,2 Gew.-% D-Panthenol;</claim-text>
<claim-text>0,215 Gew.-% Dinatrium Cocoamphodiaretat;</claim-text>
<claim-text>4,032 Gew.-% Polyoxyethylen(80)-Sorbitanmonolaurat;</claim-text>
<claim-text>0,275 Gew.-% Decylpolyglucosid;</claim-text>
<claim-text>4,3 Gew.-% Methyl Gluceth-20;</claim-text>
sowie zusätzlich Folgendes umfasst:
<claim-text>0,6 Gew.-% PEG-120 Methyl Glucose Dioleat;</claim-text>
<claim-text>87,985 Gew.-% modifizierte Ringer'sche Lösung; und</claim-text>
<claim-text>1,953 Gew.-% Wasser.</claim-text></claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verfahren zur Herstellung einer Augenlidreinigungszusammensetzung, das Folgendes umfasst:
<claim-text>a) Herstellen einer modifizierten Ringer'schen Lösung durch Mischen von Elektrolyten im Wasser;</claim-text>
<claim-text>b) Mischen von 1,2-Hexandiol, 1,2-Octandiol und einer wirksamen Menge an einem oder mehreren pH-stabilisierenden Tensiden mit der modifizierten Ringer'schen Lösung;</claim-text>
<claim-text>c) Erhitzen der Mischung;</claim-text>
<claim-text>d) Abkühlenlassen der Mischung; und</claim-text>
<claim-text>e) Versetzen der abgekühlten Mischung mit Polyhexamethylenbiguanid,<br/>
wobei die pH-stabilisierenden Tenside aus einer Gruppe bestehend aus Dinatrium Cocoamphodiaretat,<!-- EPO <DP n="28"> --> Polyoxyethylen(80)-Sorbitanmonolaurat und Decylpolyglucosid und Kombinationen davon ausgewählt sind.</claim-text></claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verfahren nach Anspruch 13, wobei Schritt (b) weiterhin das Mischen von einem oder mehreren feuchtigkeitsspendenden Mitteln mit der modifizierten Ringer'schen Lösung umfasst.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Zusammensetzung nach Anspruch 2, die Folgendes umfasst:
<claim-text>0,02 Gew.-% bis 0,3 Gew.-% Polyhexamethylenbiguanid;</claim-text>
<claim-text>0,05 Gew.-% bis 2,0 Gew.-% 1,2-Hexandiol;</claim-text>
<claim-text>0,05 Gew.-% bis 2,0 Gew.-% 1,2 Octandiol;</claim-text>
<claim-text>0,1 Gew.-% bis 25 Gew.-% Dinatrium Cocoamphodiaretat;</claim-text>
<claim-text>0,1 Gew.-% bis 10 Gew.-% Polyoxyethylen(80)-Sorbitanmonolaurat;</claim-text>
<claim-text>0,2 Gew.-% bis 10 Gew.-% Decylpolyglucosid und 60 Gew.-% bis 98 Gew.-% modifizierte Ringer'sche Lösung.</claim-text></claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Zusammensetzung nach Anspruch 15, die weiterhin Folgendes umfasst:
<claim-text>0,05 Gew.-% bis 5,0 Gew.-% D-Panthenol;</claim-text>
<claim-text>1,0 Gew.-% bis 20 Gew.-% Methyl Gluceth-20; und</claim-text>
<claim-text>0,1 Gew.-% bis 5 Gew.-% PEG-120 Methyl Glucose Dioleat.</claim-text></claim-text></claim></claims><claims mxw-id="PCLM56984925" lang="EN" load-source="patent-office"><!-- EPO <DP n="20"> --><claim id="c-en-01-0001" num="0001"><claim-text>A composition comprising:
<claim-text>polyhexamethylene biguanide;</claim-text>
<claim-text>1,2-hexanediol;</claim-text>
<claim-text>1,2-octanediol; and</claim-text>
<claim-text>a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5,<br/>
wherein the pH stabilizing surfactant solution is comprised of one or more surfactants selected from a group consisting of amphoteric surfactants, anionic surfactants, and nonionic surfactants,<br/>
wherein the amphoteric surfactants are selected from a group consisting of:
<claim-text>alkyldimethyl betaines, alkylamido betaines, sulfobetaines, and imidazoline amphoterics,</claim-text>
<claim-text>wherein the anionic surfactants are selected from a group consisting of: fatty alcohol sulfates, alpha olefin sulfonates, sulfosuccinates, sarcosinates, phosphate esters, and carboxylates and</claim-text>
<claim-text>wherein the nonionic surfactants are selected from a group consisting of: alkanolamids, ethoxylate amids, esters, alxylated alcohols, alkylpolyglucosides, amine oxides, sorbitan esters and ethoxylates.</claim-text></claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The composition of claim 1 wherein the pH stabilizing surfactant solution comprises:
<claim-text>cocoamphodiacetate disodium;</claim-text>
<claim-text>polyoxyethylene 80 sorbitan monolaurate;</claim-text>
<claim-text>decyl polyglucoside; and</claim-text>
<claim-text>a modified Ringer's solution.</claim-text></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The composition of claim 2 wherein the composition comprises:
<claim-text>0.1 wt.% to 25 wt.% cocoamphodiacetate disodium;</claim-text>
<claim-text>0.1 wt.% to 10 wit.% polyoxyethylene 80 sorbitan monolaurate;</claim-text>
<claim-text>0.2 wit.% to 10 wt.% decyl polyglucoside; and</claim-text>
<claim-text>60 wt.% to 98 wt.% modified Ringer's solution.</claim-text><!-- EPO <DP n="21"> --></claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The composition of claim 2 wherein the modified Ringer's solution comprises:
<claim-text>sodium chloride;</claim-text>
<claim-text>potassium chloride;</claim-text>
<claim-text>calcium chloride; and</claim-text>
<claim-text>water;</claim-text>
and preferably,
<claim-text>0.05 to 1.2 wt.% sodium chloride;</claim-text>
<claim-text>0.005 to 0.5 wt.% potassium chloride;</claim-text>
<claim-text>0.005 to 0.5 wt.% calcium chloride; and</claim-text>
<claim-text>water;</claim-text>
and most preferably
<claim-text>0.7 wt.% sodium chloride;</claim-text>
<claim-text>0.03 wt.% potassium chloride;</claim-text>
<claim-text>0.033 wt.% calcium chloride; and</claim-text>
<claim-text>purified water.</claim-text></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The composition of claim 1 further comprising:
<claim-text>D-panthenol;</claim-text>
<claim-text>methyl gluceth-20; and</claim-text>
<claim-text>PEG-120 methyl glucose dloleate.</claim-text></claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The composition of claim 1 further comprising one or more moisturizers, preferably selected from a group consisting of: methyl gluceth-20, sorbitol, glycerine, glycols, propylene glycol, carboxylates, amino acids, glucoside derivatives, urea, lactates, and derivatives of pantothenic acid and wherein the derivatives of pantothenic acid is most preferably selected from a group consisting of: panthenol, D-panthenol, D, L-panthenol, and combinations thereof.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The composition of claim 1 further comprising a foam stabilizer, wherein the foam stabilizer is preferably a polyethylene glycol diester of methyl glucose and a fatty acid.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The composition of claim 7 wherein the fatty acid is selected from a group consisting of oleic acid, steric acid, lauric acid, caprylic acid, and capric acid.<!-- EPO <DP n="22"> --></claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The composition of claim 1 wherein the composition is essentially free of zinc salts.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A composition of claim 2 comprising:
<claim-text>polyhexamethylene biguanide;</claim-text>
<claim-text>1,2-hexanediol;</claim-text>
<claim-text>1,2-octanediol;</claim-text>
<claim-text>cocoamphodiacetate disodium;</claim-text>
<claim-text>polyoxyethylene 80 sorbitan monolaurate;</claim-text>
<claim-text>decyl polyglucoside; and</claim-text>
<claim-text>a modified Ringer's solution,<br/>
wherein the composition further comprises one or more moisturizers, wherein the moisturizer is preferably selected from a group consisting of: methyl gluceth-20, sorbitol, glycerine, glycols, propylene glycol, carboxylates, amino acids, glucoside derivatives, urea, lactates, and derivatives of pantothenic acid.</claim-text></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The composition of claim 10 further comprising:
<claim-text>D-panthenol;</claim-text>
<claim-text>methyl gluceth-20; and</claim-text>
<claim-text>PEG-120 methyl glucose dioleate.</claim-text></claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The composition of claim 10 comprising:
<claim-text>0.04 wt.% polyhexamethylene biguanide;</claim-text>
<claim-text>0.2 wt.% 1,2-hexanediol;</claim-text>
<claim-text>0.2 wt.% 1,2-octanediol;</claim-text>
<claim-text>0.2 wt.% D-panthenol;</claim-text>
<claim-text>0.215 wt. % cocoamphodiacetate disodium;</claim-text>
<claim-text>4.032 wt.% polyoxyethylene 80 sorbitan monolaurate;</claim-text>
<claim-text>0.275 wt.% decyl polyglucoside;</claim-text>
<claim-text>4.3 wt.% methyl gluceth-20;</claim-text>
and additionally comprising
<claim-text>0.6 wt.% PEG-120 methyl glucose dioleate;</claim-text>
<claim-text>87.985 wt.% modified Ringer's Solution; and</claim-text>
<claim-text>1.953 wt% water.</claim-text><!-- EPO <DP n="23"> --></claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A method of producing an eyelid scrub composition comprising:
<claim-text>a) preparing a modified Ringer's solution by mixing electrolytes in water;</claim-text>
<claim-text>b) mixing 1,2-hexanediol, 1,2-octanediol, and an effective amount of one or more pH stabilizing surfactants with the modified Ringer's solution;</claim-text>
<claim-text>c) heating the mixture;</claim-text>
<claim-text>d) allowing the mixture to cool; and</claim-text>
<claim-text>e) adding polyhexamethylene biguanide to the cooled mixture,<br/>
wherein the pH stabilizing surfactants are selected from a group consisting of cocoamphodiacetate disodium, polyoxyethylene 80 sorbitan monolaurate and decyl polyglucoside and combinations thereof.</claim-text></claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The method of claim 13 wherein step (b) further comprises mixing one or more moisturizers with the modified Ringer's solution.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A composition according to claim 2 comprising:
<claim-text>0.02 wt.% to 0.3 wt.% polyhexamethylene biguanide;</claim-text>
<claim-text>0.05 wt.% to 2.0 wt.% 1,2-hexanediol;</claim-text>
<claim-text>0.05 wt.% to 2.0 wt.% 1,2-octanediol;</claim-text>
<claim-text>0.1 wt.% to 25 wt.% cocoamphodiacetate disodium;</claim-text>
<claim-text>0.1 wt.% to 10 wt.% polyoxyethylene-80 sorbitan monolaurate;</claim-text>
<claim-text>0.2 wt.% to 10 wt.% decyl polyglucoside; and</claim-text>
<claim-text>60 wt.% to 98 wt.% modified Ringer's Solution.</claim-text></claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>The composition of claim 15 further comprising:
<claim-text>0.05 wt.% to 5.0 wt.% D-panthenol;</claim-text>
<claim-text>1.0 wt.% to 20 wt.% methyl gluceth-20; and</claim-text>
<claim-text>0.1 wt.% to 5 wt.% PEG-120 methyl glucose dioleate</claim-text></claim-text></claim></claims><claims mxw-id="PCLM56984926" lang="FR" load-source="patent-office"><!-- EPO <DP n="29"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Composition comprenant :
<claim-text>du biguanide de polyhexaméthylène ;</claim-text>
<claim-text>du 1,2-hexanediol ;</claim-text>
<claim-text>du 1,2-octanediol ; et</claim-text>
<claim-text>une solution tensioactive stabilisant le pH, présente selon une quantité efficace pour contrôler le niveau du pH de la composition entre 5,5 et 7,5 ;<br/>
dans laquelle la solution tensioactive stabilisant le pH est constituée d'un ou plusieurs agents tensioactifs choisis dans le groupe constitué par les agents tensioactifs amphotères, les agents tensioactifs anioniques et les agents tensioactifs non ioniques,<br/>
où les agents tensioactifs amphotères sont choisis dans le groupe constitué par les alkyldiméthylbétaïnes, les alkylamidobétaïnes, les sulfobétaïnes et les substances amphotères à base d'imidazoline ;<br/>
où les agents tensioactifs anioniques sont choisis dans le groupe constitué par les sulfates d'alcool gras, les sulfonates d'alpha-oléfines, les sulfosuccinates, les sarcosinates, les esters de phosphate et les carboxylates ; et<br/>
où les agents tensioactifs non ioniques sont choisis dans le groupe constitué par les alcanolamides, les amides éthoxylés, les esters, les alcools alcoxylés, les alkylpolyglucosides, les oxydes d'amine, les esters et éthoxylates de sorbitane.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composition selon la revendication 1, dans<!-- EPO <DP n="30"> --> laquelle la solution tensioactive stabilisant le pH comprend :
<claim-text>du cocoamphodiacétate disodique ;</claim-text>
<claim-text>du monolaurate de sorbitane polyoxyéthyléné 80 ;</claim-text>
<claim-text>du décyl-polyglucoside ; et</claim-text>
<claim-text>une solution de Ringer modifiée.</claim-text></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composition selon la revendication 2, <b>caractérisée en ce que</b> la composition comprend :
<claim-text>de 0,1% en poids à 25% en poids de cocoamphodiacétate disodique ;</claim-text>
<claim-text>de 0,1% en poids à 10% en poids de monolaurate de sorbitane polyoxyéthyléné 80 ;</claim-text>
<claim-text>de 0,2% en poids à 10% en poids de décyl-polyglucoside ; et</claim-text>
<claim-text>de 60% en poids à 98% en poids d'une solution de Ringer modifiée.</claim-text></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composition selon la revendication 2, <b>caractérisée en ce que</b> la solution de Ringer modifiée comprend :
<claim-text>du chlorure de sodium ;</claim-text>
<claim-text>du chlorure de potassium ;</claim-text>
<claim-text>du chlorure de calcium ; et</claim-text>
<claim-text>de l'eau ;</claim-text>
et préférablement,
<claim-text>de 0,05 à 1,2% en poids de chlorure de sodium ;</claim-text>
<claim-text>de 0,005 à 0,5% en poids de chlorure de potassium ;</claim-text>
<claim-text>de 0,005 à 0,5% en poids de chlorure de calcium ; et</claim-text>
<claim-text>de l'eau ;</claim-text>
et tout préférablement,
<claim-text>0,7% en poids de chlorure de sodium ;</claim-text>
<claim-text>0,03% en poids de chlorure de potassium ;</claim-text>
<claim-text>0,033% en poids de chlorure de calcium ; et</claim-text>
<claim-text>de l'eau purifiée.</claim-text></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Composition selon la revendication 1, comprenant en outre :<!-- EPO <DP n="31"> -->
<claim-text>du D-panthénol ;</claim-text>
<claim-text>de l'éther de méthylglucose 20 ; et</claim-text>
<claim-text>du dioléate de méthylglucose et de PEG-120.</claim-text></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Composition selon la revendication 1, comprenant en outre un ou plusieurs hydratants, choisis de préférence dans le groupe constitué par l'éther de méthylglucose 20, le sorbitol, le glycérol, les glycols, le propylène glycol, les carboxylates, les acides aminés, les dérivés de glucoside, l'urée, les lactates, et les dérivés d'acide pantothénique et où les dérivés d'acide pantothénique sont choisis tout préférablement dans le groupe constitué par le panthénol, le D-panthénol, le D,L-panthénol, et des combinaisons de ceux-ci.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Composition selon la revendication 1, comprenant en outre un stabilisant de mousse, où le stabilisant de mousse est préférablement un diester de polyéthylène glycol de méthylglucose et d'un acide gras.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Composition selon la revendication 7, <b>caractérisée en ce que</b> l'acide gras est choisi dans le groupe constitué par l'acide oléique, l'acide stéarique, l'acide laurique, l'acide caprylique et l'acide caprique.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Composition selon la revendication 1, <b>caractérisée en ce que</b> la composition est essentiellement dépourvue de sels de zinc.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Composition selon la revendication 2, comprenant :
<claim-text>du biguanide de polyhexaméthylène ;</claim-text>
<claim-text>du 1,2-hexanediol ;</claim-text>
<claim-text>du 1,2-octanediol ;</claim-text>
<claim-text>du cocoamphodiacétate disodique ;</claim-text>
<claim-text>du monolaurate de sorbitane polyoxyéthyléné 80 ;</claim-text>
<claim-text>du décyl-polyglucoside ; et</claim-text>
<claim-text>une solution de Ringer modifiée ;</claim-text><!-- EPO <DP n="32"> -->
<b>caractérisée en ce que</b> la composition comprend en outre un ou plusieurs hydratants, où l'hydratant est choisi de préférence dans le groupe constitué par l'éther de méthylglucose 20, le sorbitol, le glycérol, les glycols, le propylène glycol, les carboxylates, les acides aminés, les dérivés de glucoside, l'urée, les lactates, et les dérivés d'acide pantothénique.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Composition selon la revendication 10, comprenant en outre :
<claim-text>du D-panthénol ;</claim-text>
<claim-text>de l'éther de méthylglucose 20 ; et</claim-text>
<claim-text>du dioléate de méthylglucose et de PEG-120.</claim-text></claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Composition selon la revendication 10, comprenant :
<claim-text>0,04% en poids de biguanide de polyhexaméthylène ;</claim-text>
<claim-text>0,2% en poids de 1,2-hexanediol ;</claim-text>
<claim-text>0,2% en poids de 1,2-octanediol ;</claim-text>
<claim-text>0,2% en poids de D-panthénol ;</claim-text>
<claim-text>0,215% en poids de cocoamphodiacétate disodique ;</claim-text>
<claim-text>4,032% en poids de monolaurate de sorbitane polyoxyéthyléné 80 ;</claim-text>
<claim-text>0,275% en poids de décyl-polyglucoside ;</claim-text>
<claim-text>4,3% en poids d'éther de méthylglucose 20 ;</claim-text>
et comprenant en outre
<claim-text>0,6% en poids de dioléate de méthylglucose et de PEG-120 ;</claim-text>
<claim-text>87,985% en poids d'une solution de Ringer modifiée ; et</claim-text>
<claim-text>1,953% en poids d'eau.</claim-text></claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Méthode de production d'une composition de gommage pour paupières, comprenant les étapes consistant à :
<claim-text>a) préparer une solution de Ringer modifiée par le mélange d'électrolytes dans de l'eau ;</claim-text>
<claim-text>b) mélanger du 1,2-hexanediol, du 1,2-octanediol, et une quantité efficace d'un ou plusieurs agents tensioactifs stabilisant le pH avec la solution de<!-- EPO <DP n="33"> --> Ringer modifiée ;</claim-text>
<claim-text>c) chauffer le mélange ;</claim-text>
<claim-text>d) laisser refroidir le mélange ; et</claim-text>
<claim-text>e) ajouter du biguanide de polyhexaméthylène au mélange refroidi ;</claim-text>
où les agents tensioactifs stabilisant le pH sont choisis dans le groupe constitué par le cocoamphodiacétate disodique, le monolaurate de sorbitane polyoxyéthyléné 80 et le décyl-polyglucoside, et des combinaisons de ceux-ci.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Méthode selon la revendication 13, dans laquelle l'étape (b) comprend en outre le mélange d'un ou plusieurs hydratants avec la solution de Ringer modifiée.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Composition selon la revendication 2, comprenant :
<claim-text>de 0,02% en poids à 0,3% en poids de biguanide de polyhexaméthylène ;</claim-text>
<claim-text>de 0,05% en poids à 2,0% en poids de 1,2-hexanediol ;</claim-text>
<claim-text>de 0,05% en poids à 2,0% en poids de 1,2-octanediol ;</claim-text>
<claim-text>de 0,1% en poids à 25% en poids de cocoamphodiacétate disodique ;</claim-text>
<claim-text>de 0,1% en poids à 10% en poids de monolaurate de sorbitane polyoxyéthyléné 80 ;</claim-text>
<claim-text>de 0,2% en poids à 10% en poids de décyl-polyglucoside ; et</claim-text>
<claim-text>de 60% en poids à 98% en poids d'une solution de Ringer modifiée.</claim-text></claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Composition selon la revendication 15, comprenant en outre :
<claim-text>de 0,05% en poids à 5,0% en poids de D-panthénol ;</claim-text>
<claim-text>de 1,0% en poids à 20% en poids d'éther de méthylglucose 20 ; et</claim-text>
<claim-text>de 0,1% en poids à 5% en poids de dioléate de méthylglucose et de PEG-120.</claim-text></claim-text></claim></claims><drawings mxw-id="PDW16672002" load-source="patent-office"><!-- EPO <DP n="34"> --><figure id="f0001" num="1,2"><img id="if0001" file="imgf0001.tif" wi="134" he="201" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
